T1	Participants 426 716	All patients were treated with CsA for the first 10 days and then randomized to receive Evr in combination with CsA up to day 30, then either continued on Evr monotherapy (Evr group) or maintained on CsA with/without mycophenolate mofetil (CsA group) in case of chronic kidney disease (CKD)
T2	Participants 718 782	Seventy-eight patients were randomized (Evr n = 52; CsA n = 26).
